AACR 2026 – Circle’s focus narrows
First-in-human results prompt a biomarker-defined approach for CID-078.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
Allogene finds a way forward for allogeneic Car-T
After setbacks, cema-cel might have a path to approval in lymphoma.
Ideaya’s darovasertib plan comes together
Optimum-02 virtually replicates phase 1, and a filing will follow.
Oric gets a reality check
Rinzimetostat efficacy wanes further as the company moves into phase 3.
